A beneficial effect of high ABCC3 expression was also seen in a previous study evaluating DFS in patients with stage III CRC undergoing adjuvant FLV‐based combination chemotherapy according to the Nordic bolus regime [14]. The gene discussed is ABCC3; the disease is colorectal carcinoma.